Channel Therapeutics Corporation Stock Price, News & Analysis

Channel Therapeutics Corporation, which has traded on the NYSE American under the ticker symbol CHRO, is described in its public communications as a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The company’s initial clinical focus is on selectively targeting the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks.

The company has highlighted NaV1.7 as a genetically validated sodium channel target involved in pain transmission. Its disclosures explain that overexpression of NaV1.7 activity is associated with severe pain conditions, and that modulation or inhibition of this channel may provide a mechanism for decreasing pain without relying on opioid-based therapies. Channel Therapeutics has emphasized a multi-pronged approach to NaV1.7 inhibition through different formulations and routes of administration.

Business focus and therapeutic programs

According to multiple news releases, Channel Therapeutics has described several key programs built around NaV1.7 inhibition:

• Oral NaV1.7 inhibitor program aimed at systemic chronic pain conditions. The company has referenced neuropathic pain indications, including idiopathic small fiber neuropathy and erythromelalgia, as part of its planned clinical focus for oral NaV1.7 inhibitors.
• Eye pain program (CT2000), an eye drop formulation of a NaV1.7 inhibitor for the treatment of acute ocular pain and chronic ocular surface pain commonly associated with dry eye disease. In preclinical in vivo models, Channel Therapeutics reported that CT2000 reduced surrogate measures of ocular pain in animal studies involving acute insult and dry eye models.
• Injectable depot program for post-operative nerve blocks, using a NaV1.7 inhibitor in peripheral nerve block formulations for acute and post-surgical pain. The company has reported preclinical in vivo nerve block data in rodent models, where multiple depot formulations showed a sustained effect over several days and were compared with bupivacaine, a commonly used local anesthetic.

Across these programs, Channel Therapeutics has consistently described its goal as developing non-opioid, non-addictive pain therapeutics that may address chronic neuropathic pain, eye pain, and post-surgical pain, while potentially reducing reliance on opioid medications.

Corporate evolution and name change

The company previously operated under the name Chromocell Therapeutics Corporation. A news release states that on November 18, 2024, Chromocell Therapeutics Corporation changed its name to Channel Therapeutics Corporation and reincorporated in the State of Nevada. The company explained that the new name “Channel Therapeutics” was chosen to reflect its focus on therapeutics based on sodium channel modulation and blockade for the treatment of pain, with particular emphasis on NaV1.7.

Following the name change, Channel Therapeutics continued to describe itself as a clinical-stage biotechnology company developing non-opioid, non-addictive therapeutics targeting NaV1.7 for chronic neuropathic pain, acute and chronic eye pain, and post-surgical nerve blocks. The company also announced program updates for its depot nerve block and eye pain programs, as well as plans for further development work in chronic pain.

Merger and transition to Pelthos Therapeutics

Subsequent disclosures describe a significant corporate transaction affecting the CHRO ticker. A news release and a Form 8-K report that Channel Therapeutics Corporation entered into a merger agreement involving CHRO Merger Sub, Inc., LNHC, Inc., and Ligand Pharmaceuticals Incorporated. On July 1, 2025, the merger closed, with Merger Sub merging with and into LNHC, and LNHC surviving as a wholly owned subsidiary of the company.

In connection with this transaction, the company’s name was changed from Channel Therapeutics Corporation to Pelthos Therapeutics Inc., and its shares were set to trade on the NYSE American exchange under the new ticker symbol PTHS starting on July 2, 2025. A separate news release explains that the combined company will operate under the name Pelthos Therapeutics Inc. and that the CHRO common stock would begin trading under the name Pelthos Therapeutics Inc. and, upon consummation of the transactions, under the symbol PTHS.

After the merger, Pelthos Therapeutics is described as a biopharmaceutical company committed to commercializing therapeutic products for high unmet patient needs, with a lead product, ZELSUVMI (berdazimer) topical gel, 10.3%, for the treatment of molluscum contagiosum in adults and pediatric patients one year of age and older. ZELSUVMI is characterized as a nitric oxide-releasing topical gel and the first and only prescription medication approved for at-home application by patients, parents, or caregivers to treat this viral skin infection. While this description pertains to Pelthos Therapeutics under the PTHS symbol, it is part of the corporate lineage that originated from Channel Therapeutics Corporation under the CHRO symbol.

Contribution of NaV1.7-related assets

The Form 8-K filed on July 2, 2025 describes a contribution of certain NaV1.7-related assets. On July 1, 2025, the company entered into a Contribution Agreement with a newly formed, wholly owned subsidiary, Channel Pharmaceutical Corporation. Under this agreement, the company contributed assets associated with non-opioid, non-addictive therapeutics to alleviate pain, including patents, know-how, and other technology relating to NaV1.7 for systemic chronic pain, acute and chronic eye pain, and post-surgical nerve blocks. These assets were transferred to the subsidiary, which may engage in licensing, developing, and commercializing the related intellectual property.

This structure indicates that the NaV1.7 pain programs that were central to Channel Therapeutics’ business focus are held in a subsidiary following the merger and corporate name change to Pelthos Therapeutics Inc. The 8-K also references royalty agreements related to ZELSUVMI and other products or technologies, but those details relate to Pelthos and its subsidiaries following the transaction rather than to CHRO as a standalone entity.

Trading status and historical context for CHRO

Based on the company’s own announcements, the CHRO ticker historically represented Chromocell Therapeutics Corporation and then Channel Therapeutics Corporation, both of which focused on NaV1.7-based, non-opioid pain therapeutics. With the completion of the merger and the name change to Pelthos Therapeutics Inc., the company’s shares are described as trading on the NYSE American under the symbol PTHS starting on July 2, 2025. The news releases state that, upon consummation of the transactions, the trading symbol for the company’s common stock will be PTHS.

Investors researching CHRO stock are therefore looking at the historical identity and activities of Chromocell Therapeutics Corporation and Channel Therapeutics Corporation, as well as the transition into Pelthos Therapeutics Inc. under a different trading symbol. The NaV1.7 pain programs, the depot nerve block program, and the eye pain program form part of this historical record, while the current commercial focus described in the most recent news relates to Pelthos Therapeutics and its lead dermatology product, ZELSUVMI.

Sector and industry classification

In the provided classification, CHRO is associated with the sector "Biological Products". Public communications consistently describe the business as a clinical-stage biotechnology or biopharmaceutical company, emphasizing research, development, and potential commercialization of therapeutics rather than diagnostics or devices. The company’s focus on sodium channel modulation, NaV1.7 inhibition, and non-opioid pain therapeutics places it within the broader biopharmaceutical and biotechnology space.

Key themes in Channel Therapeutics’ strategy

From the available disclosures, several themes recur in Channel Therapeutics’ description of its strategy and programs:

• Emphasis on non-opioid, non-addictive pain therapeutics as an alternative to traditional opioid-based pain management.
• Focus on NaV1.7 as a genetically validated target for pain, with the belief that inhibition of NaV1.7 can reduce pain severity.
• Development of multiple formulations and routes of administration (oral, eye drops, injectable depot nerve blocks) to address different pain indications, including chronic neuropathic pain, ocular pain, and post-surgical pain.
• Progression through preclinical in vivo models to demonstrate efficacy and support further clinical development.
• Corporate restructuring and transactions, including the name change from Chromocell Therapeutics Corporation to Channel Therapeutics Corporation, reincorporation in Nevada, and the later merger and name change to Pelthos Therapeutics Inc., with a new trading symbol.

These elements define the historical profile of Channel Therapeutics Corporation under the CHRO ticker and provide context for understanding how the company’s NaV1.7-based pain programs fit into the broader corporate evolution that led to Pelthos Therapeutics Inc.

FAQs about Channel Therapeutics Corporation (historical CHRO)